Brassicasterol inhibits hepatitis B virus-associated hepatocellular carcinoma development via suppression of AKT signaling pathway

Brassicasterol inhibits hepatitis B virus-associated hepatocellular carcinoma development via suppression of AKT signaling pathway

Abstract Background Hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) does not respond well to current treatment options like sorafenib, and there is an urgent need for developing therapeutical strategies for HBV + HCC. Brassicasterol has previously shown anti-cancer and anti-viral a...

Full description

Bibliographic Details
Main Authors: Jindi Zeng, Jiancheng Wu, Shuijiao Pang, Feifei Wang, Xin Yu, Shouhua Zhang, Junquan Zeng, Jinlong Yan, Jianping Lian
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Infectious Agents and Cancer
Subjects:
Brassicasterol
Hepatitis B virus
Inhibition
Hepatocellular carcinoma
Online Access:https://doi.org/10.1186/s13027-023-00502-1

Internet

https://doi.org/10.1186/s13027-023-00502-1

Similar Items